Title |
Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses
|
---|---|
Published in |
BMC Medical Genomics, October 2011
|
DOI | 10.1186/1471-2350-12-131 |
Pubmed ID | |
Authors |
Stella Trompet, Anton JM de Craen, Iris Postmus, Ian Ford, Naveed Sattar, Muriel Caslake, David J Stott, Brendan M Buckley, Frank Sacks, James J Devlin, P Eline Slagboom, Rudi GJ Westendorp, J Wouter Jukema, the PROSPER study group |
Abstract |
The PHArmacogenetic study of Statins in the Elderly at risk (PHASE) is a genome wide association study in the PROspective Study of Pravastatin in the Elderly at risk for vascular disease (PROSPER) that investigates the genetic variation responsible for the individual variation in drug response to pravastatin. Statins lower LDL-cholesterol in general by 30%, however not in all subjects. Moreover, clinical response is highly variable and adverse effects occur in a minority of patients. In this report we first describe the rationale of the PROSPER/PHASE project and second show that the PROSPER/PHASE study can be used to study pharmacogenetics in the elderly. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Australia | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 2% |
Unknown | 62 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 12 | 19% |
Researcher | 10 | 16% |
Student > Master | 9 | 14% |
Other | 7 | 11% |
Student > Bachelor | 4 | 6% |
Other | 6 | 10% |
Unknown | 15 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 18 | 29% |
Agricultural and Biological Sciences | 12 | 19% |
Biochemistry, Genetics and Molecular Biology | 8 | 13% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
Nursing and Health Professions | 2 | 3% |
Other | 3 | 5% |
Unknown | 17 | 27% |